Recently, Hammarsten et al. reported that metabolic syndrome and its components may hinder the diagnosis of low-stage PCa by a mechanism that reduces serum prostate-specific antigen (PSA) level [17]. This evidence concerns the gene KLK3 and metabolic syndrome.